Clinical trial
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene…
NCT00228488 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00228488 |
|---|---|
| Title | Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma |
| Official title | Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ® |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 60 |
| Start date | Jun 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Sep 29, 2005 |
| Last update posted | Dec 19, 2007 |
| Countries | Hong Kong, Singapore |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: